Sonoma Pharmaceuticals Inc.
SNOA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.99M
Close$
$-2.92
354% downside
Current Fair Value
354% downsideOvervalued by 354% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.99 Million |
|---|---|
| Enterprise Value | $6.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.89 |
| Beta | 1.3 |
| Outstanding Shares | 1,764,331 |
Return
| Return on Equity | -102.58% |
|---|---|
| Return on Assets | -22.74% |
| Return on Invested Capital | -31.67% |
Valuation & Multiples
| P/E Ratio | -0.61 |
|---|---|
| PEG | 2.42 |
| Price to Sales | 0.1 |
| Price to Book Ratio | 1.15 |
| Enterprise Value to Revenue | 0.35 |
| Enterprise Value to EBIT | -2.39 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 1.06 |
| Debt to Equity | 2.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 16, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$5.57 M
Average shareholder expectationNext Earnings Call
Expected Date
July 15, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$5.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.94%▼ 2.42% |
|---|---|
| Total Invested | $143,701▼ 63.75% |
| Investors Holding | 17▲ 2.00% |
ESG Score
No data
About Sonoma Pharmaceuticals Inc.
CEO: Amy Trombly